Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its earnings results on Wednesday. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.46, Briefing.com reports. The company had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same period last year, the firm posted ($1.19) EPS. Sarepta Therapeutics’s quarterly revenue was up 350000.0% compared to the same quarter last year.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 40.93 on Friday. The firm’s market cap is $2.25 billion. The company has a 50-day moving average of $33.69 and a 200-day moving average of $32.07. Sarepta Therapeutics has a 1-year low of $22.61 and a 1-year high of $63.73.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock valued at $280,000 after buying an additional 129 shares during the last quarter. Sigma Planning Corp boosted its position in Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 930 shares during the last quarter. Bank of Montreal Can boosted its position in Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Sarepta Therapeutics by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock valued at $7,339,000 after buying an additional 1,923 shares during the last quarter. Finally, Stifel Financial Corp boosted its position in Sarepta Therapeutics by 19.3% in the first quarter. Stifel Financial Corp now owns 13,366 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 2,165 shares during the last quarter. Hedge funds and other institutional investors own 73.13% of the company’s stock.
SRPT has been the topic of several research analyst reports. SunTrust Banks, Inc. boosted their target price on shares of Sarepta Therapeutics from $30.00 to $31.00 in a report on Thursday, April 6th. Oppenheimer Holdings, Inc. set a $76.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Sunday, March 26th. Vetr downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $37.67 price target on the stock. in a research note on Monday, April 24th. Cowen and Company reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday, April 28th. Finally, Piper Jaffray Companies set a $43.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 18th. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and an average target price of $61.18.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
